Drug Profile

Research programme: cannabinoid receptor modulators - CeNeRx BioPharma

Alternative Names: CXB 006; CXB 029; CXB 040; CXB070; NESS 006A; NESS040C5; NESS070C5

Latest Information Update: 28 Jun 2013

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PharmaNess Neuroscience
Developer CeNeRx BioPharma
Class Cannabinoids
Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB1 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

28 Jun 2013 Discontinued - Preclinical for Glaucoma in USA (unspecified route)
28 Jun 2013 Discontinued - Preclinical for Obesity in USA (unspecified route)
28 Jun 2013 Discontinued - Preclinical for Pain in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com